Featured Stories

Lilly Looks To Take POINT On Emerging Cancer Radiopharmaceutical Space
Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a strong position in an emerging field.

Podcast: How Will Greater FTC Scrutiny Affect Biopharma M&A Activity?
Scrip’s Joseph Haas and Jessica Merrill discuss the US FTC’s oversight of the Amgen/Horizon deal and what it might portend for biopharma M&A with Leerink Partners' Dan Lepanto and ZS partner Cody Powers.

J&J And Sanofi Team Up On Phase III E. Coli Vaccine
Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.
Asia Spotlight
Sun Backs India-First Stroke Drug From Pharmazz
Sun debuts Pharmazz Inc’s new stroke drug sovateltide in India at under $20/ vial. The selective endothelin-B receptor agonist, which can be administered up to 24 hours post cerebral ischemic stroke, is also being studied in Alzheimer’s disease.
Latest News
Scrip Originals

Pipeline Watch: Japan Dominates This Week's 26 Approvals Plus 13 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Stock Watch: The Rise Of Biotech Platforms
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely to shepherd an exit from the current doldrums, though.

Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
Interviews

Pneumagen Plots Entry Into COPD Space With Neumifil
With positive results from a Phase II proof of concept controlled human infection model study evaluating Neumifil under its belt, the Scottish biotech is preparing to put the drug through its paces in a chronic obstructive pulmonary disease trial next year.

Achieve Life Sciences Believes It Has The New Chantix
Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market.

Ex-Novartis John Tsai Takes The Reins At Cardiovascular-Focused Forcefield Therapeutics
The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.

Newly Unveiled Ampersand's CEO On ‘Programmable’ Medicines And Flagship’s Winning Formula
Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.
Graphics

ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.

Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D
After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.

Top 10 Best-Selling Drugs Of Q2 2023: COVID-19 Out, HPV In
The Merck & Co vaccine for human papillomavirus Gardasil, along with Johnson & Johnson’s Darzalex for multiple myeloma, entered the ranks of the top 10 best-selling drugs globally in the second quarter. There was no product for COVID-19 in the line-up for the first time since 2020.

A Closer Look: Commercial Impact For Drugs Up For Medicare Price Negotiation
An infographic looking at commercial factors for the 10 drugs chosen for Medicare price negotiation in 2026 under the Inflation Reduction Act (IRA). The graphics below review the valuations of these drugs, both past and forecast, as well as their relative contributions to the top-lines of the companies that own them.
Recent Stories
Exkivity Withdrawal Is Blow To Takeda’s Oncology Ambitions
The withdrawal of the targeted anticancer comes as no surprise after its Phase III missed in July, but it sets back Takeda’s expansion plans in the competitive therapy area.
Pipeline Watch: Japan Dominates This Week's 26 Approvals Plus 13 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
IRA Litigation Hurdles Clarified With Ruling In Chamber Of Commerce Suit
Drug manufacturers will have to participate in the Medicare drug price negotiation process for the foreseeable future. Judge Newman's finding that participation in Medicare is voluntary could defeat constitutional challenges to the program and have an impact on other cases.
Japan Approves Leqembi, All Eyes Now On Extended Pricing Discussions
Japan's latest batch of product approvals includes high-profile Alzheimer's drug Leqembi (lecanemab), along with Alhemo (concizumab) for hemophilia, Phozevel (tenapanor) for hyperphosphatemia and others. Eyes are now on the shape of use guidelines and monitoring requirements for Leqembi, along with how its extended NHI reimbursement pricing process will develop. All going well, it could reach the market by the end of the year.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: major Q4 catalysts; Verona’s COPD contender; Alfasigma acquires Intercept; more setbacks for Keytruda/Lenvima combo; and new pressures on China IPOs.
Syndax Readies FDA Filing In Leukemia After Stopping Revumenib Trial Early For Efficacy
The AUGMENT-101 study showed a strong response rate among acute leukemia patients who historically have a poor prognosis.
ICER Hands CMS A Drug Price Negotiation Cheat Sheet
The drug price assessment group ran cost analyses on two of the first 10 drugs selected for Medicare price negotiations, Eliquis and Xarelto, and submitted the report to the US government.
Muted APPLAUSE For Novartis In IgAN
A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.
Stock Watch: The Rise Of Biotech Platforms
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely to shepherd an exit from the current doldrums, though.
Pneumagen Plots Entry Into COPD Space With Neumifil
With positive results from a Phase II proof of concept controlled human infection model study evaluating Neumifil under its belt, the Scottish biotech is preparing to put the drug through its paces in a chronic obstructive pulmonary disease trial next year.
Life Sciences Scaling Adoption Of New Metaverse, AI Tools
Life sciences firms are increasingly adopting new technologies like the metaverse and piloting use cases, although a "truly 3D immersive customer experience" may be some distance away. But 2024 could see an inflection point with increasing demand for certain metaverse applications, says a senior Indegene executive.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.